91ÌÒÉ«

Ground-breaking Lipid Nanoparticles, patented for efficient delivery of RNA-based vaccines and therapeutics, offer long-term stability at ambient temperatures, eliminating the need for costly cold-chain storage.

This innovation ensures high efficacy for at least 12 months, whether in aqueous or powder form, even in tropical climates reaching up to 40°C. With a validation study underway with a world-leading pharmaceutical company, our spinout aims to license-out and co-develop our technologies with RNA vaccines and therapeutics developers.

Media:

About us | 91ÌÒÉ« groups | 91ÌÒÉ«

GSK and 91ÌÒÉ« to eliminate costly cold-chain storage of RNA vaccines | 91ÌÒÉ« News | 91ÌÒÉ«

91ÌÒÉ« and GSK extend collaboration to tackle global vaccine cold-chain limits | 91ÌÒÉ« News | 91ÌÒÉ«